HOME Top Market Reports NGS-based RNA-seq Market by Products & Services (Sample Preparation, Consumables, Bioinformatics), Technology (SBS, SMRT), Application (De novo, Transcriptome Epigenetics, Small RNA), End User (Research Centers, BioPharma Companies) - Global Forecast to 2022

NGS-based RNA-seq Market by Products & Services (Sample Preparation, Consumables, Bioinformatics), Technology (SBS, SMRT), Application (De novo, Transcriptome Epigenetics, Small RNA), End User (Research Centers, BioPharma Companies) - Global Forecast to 2022

By: marketsandmarkets.com
Publishing Date: May 2017
Report Code: BT 5297

 

  Speak to Analyst Enquiry Before Buying Webinar
purchase report
download pdf  request for customisation


The global NGS-based RNA-seq market is projected to reach USD  2.65 Billion by 2022 from USD 1.05 Billion in 2017, at a CAGR of 20.2%.

Objectives of the study are:

  • To define, describe, and forecast the NGS-based RNA-seq market on the basis of product & service, technology, application, end user, and region
  • To provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, opportunities, and industry-specific challenges) along with the current trends
  • To strategically analyze micromarkets with respect to their individual growth trends, prospects, and contributions to the total market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the revenue of the market segments with respect to four regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW)
  • To profile the key players and comprehensively analyze their market shares and core competencies
  • To track and analyze competitive developments such as product launches; agreements, partnerships, and collaborations; mergers & acquisitions; and R&D activities in the NGS-based RNA-Seq market

This research study involved extensive secondary sources; directories; and databases such as Hoover’s, Bloomberg Business, Factiva, and Avention; along with government databases, to identify and collect information useful for this technology-based, market-oriented, and commercial study of the NGS-based RNA-seq market. In-depth interviews were conducted with various primary respondents that mainly included key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants to obtain and verify critical qualitative and quantitative information as well as assess prospects. The secondary resources include, National Cancer Institute (NCI), European Society of Human Genetics (ESHG), Asia Pacific Society of Human Genetics (APSHG), National Institutes of Health (NIH), American Chemical Society, National Human Genome Research Institute (NHGRI), American Society of Clinical Oncology (ASCO), European Molecular Biology Laboratory (EMBL), American Association for Cancer Research (AACR), The RNA Society, Genome Canada, Annual Reports, SEC Filings, Press Releases, Investor Presentations, Journals, Food and Drug Administration (FDA), World Health Organization (WHO), Organisation for Economic Co-operation and Development (OECD), World Bank, Department of Biotechnology (DBT), American Cancer Society, GLOBOCAN 2012, Biotechnology and Biological Sciences Research Council (BBSRC), Expert Interviews, and MarketsandMarkets Analysis.

NGS-based RNA-seq Market

To know about the assumptions considered for the study, download the pdf brochure

As of 2016, Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Pacific Biosciences of California, Inc. (U.S.), holds the leading position in the global NGS-based RNA-seq market. In the past three years, these companies adopted product launches & product enhancements, agreements, collaborations, and partnerships as their key business strategies to ensure market dominance. QIAGEN N. V. (Germany), BGI (China), Oxford Nanopore Technologies, Ltd. (U.K.), PerkinElmer, Inc. (U.S.), GATC Biotech AG (Germany), Agilent Technologies, Inc. (U.S.), Roche Holding AG (Switzerland), Macrogen, Inc. (South Korea), and Eurofins Scientific (Luxembourg) are some of the other major players in this market.

Stakeholders

  • NGS equipment manufacturers, vendors, and distributors
  • NGS sequencing services companies
  • NGS bioinformatics/data analysis companies
  • Research institutes and government organizations
  • Venture capitalists and other government funding organizations
  • Research and consulting firms
  • Healthcare institutions (hospitals and medical schools)
  • Pharmaceutical and biotechnology companies
  • Contract manufacturing organizations (CMOS)
  • Contract research organizations (CROS)

Scope of the Report

This report categorizes the global NGS-based RNA-Seq market into the following segments and subsegments:

Global NGS-based RNA-Seq Market, by Product & Service

  • Sample Preparation
    • Sample Preparation
      • Fragmentation, End Repair, and Size Selection
      • Library Preparation & Target Enrichment
      • Quality Control
    • Sample Preparation, by Method
      • Manual
      • Microfluidics
      • Robotic & Liquid Handling
  • Sequencing Platforms & Consumables for RNA-Seq
  • RNA Sequencing Services
  • Data Analysis, Storage, and Management

Global NGS-based RNA-Seq Market, by Technology

  • Sequencing by Synthesis (SBS)
  • Ion Semiconductor Sequencing
  • Single-molecule Real-time (SMRT) Sequencing
  • Nanopore Sequencing

Global NGS-based RNA-Seq Market, by Application

  • De Novo Transcriptome Assembly
  • Expression Profiling Analysis
  • Variant Calling and Transcriptome Epigenetics
  • Small RNA Sequencing

Global NGS-based RNA-Seq Market, by End User

  • Research Centers and Academic & Government Institutes
  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Other End Users (Non-profit Organizations, Agrigenomics Organizations, and Consumer Genomics Companies)

Global NGS-based RNA-Seq Market, by Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

Geographic Analysis

  • Further breakdown of the regional NGS-based RNA-Seq market into countries:
  • North America into U.S. and Canada
  • Europe into Germany, France, U.K., and Rest of Europe
  • Asia-Pacific into China, Japan, India, and Rest of Asia-Pacific

Table of Contents

1 Introduction (Page No. - 14)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Geographic Scope
           1.3.3 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 18)
    2.1 Research Methodology Steps
    2.2 Research Design
    2.3 Secondary and Primary Research Methodology
           2.3.1 Secondary Research
                    2.3.1.1 Key Data From Secondary Sources
           2.3.2 Primary Data
                    2.3.2.1 Key Data From Primary Sources
                    2.3.2.2 Key Industry Insights
    2.4 Market Size Estimation
           2.4.1 Bottom-Up Approach
           2.4.2 Top-Down Approach
    2.5 Market Breakdown and Data Triangulation
    2.6 Assumptions for the Study

3 Executive Summary (Page No. - 28)
    3.1 Introduction

4 Premium Insights (Page No. - 33)
    4.1 NGS-based RNA-seq Market Overview
    4.2 Market Growth Rate, By Technology, 2017 vs 2022 (USD Million)
    4.3 Market, By Application and Region, 2017 (USD Million)
    4.4 Market, By End User, 2017 vs 2022
    4.5 Geographical Snapshot of the Market

5 Market Overview (Page No. - 36)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Advantages of RNA-seq Over Microarray Technology
                    5.2.1.2 Technological Advancements in RNA-seq Products
                    5.2.1.3 Increasing Number of RNA-seq Grants
                    5.2.1.4 Increasing Number of Research Activities Involving RNA-seq
                    5.2.1.5 Rapid Growth in Precision Medicine
           5.2.2 Restraints
                    5.2.2.1 Lack of Skilled Professionals
                    5.2.2.2 Standardization Concerns of RNA-seq in Diagnostic Testing
           5.2.3 Opportunities
                    5.2.3.1 Increasing Applications of RNA-seq in Research
                               5.2.3.1.1 Cancer Research
                               5.2.3.1.2 Agricultural Research
           5.2.4 Challenges
                    5.2.4.1 Storage & Interpretation of Sequencing Data
                    5.2.4.2 Analysis of RNA-seq Data for Detection of Novel Transcripts
    5.3 Industry Trends
           5.3.1 Growing Number of Strategic Partnerships and Collaborations
           5.3.2 Increasing Number of Conferences and Workshops Related to RNA-seq

6 Global NGS-based RNA Sequencing Market, By Product & Service (Page No. - 46)
    6.1 Introduction
           6.1.1 Sample Preparation
                    6.1.1.1 Sample Preparation, By Workflow Step
                               6.1.1.1.1 Fragmentation, End Repair, and Size Selection
                               6.1.1.1.2 Library Preparation and Target Enrichment
                               6.1.1.1.3 Quality Control
                    6.1.1.2 Sample Preparation, By Method
                               6.1.1.2.1 Manual Sample Preparation
                               6.1.1.2.2 Microfluidic Sample Preparation
                               6.1.1.2.3 Robotic Liquid Handling Sample Preparation
           6.1.2 Sequencing Platforms and Consumables
           6.1.3 Sequencing Services
           6.1.4 Data Analysis, Storage, and Management

7 Global NGS-based RNA Sequencing Market, By Technology (Page No. - 58)
    7.1 Introduction
    7.2 Sequencing By Synthesis
    7.3 Ion Semiconductor Sequencing
    7.4 Single-Molecule Real-Time Sequencing
    7.5 Nanopore Sequencing

8 Global NGS-based RNA Sequencing Market, By Application (Page No. - 66)
    8.1 Introduction
    8.2 Expression Profiling Analysis
    8.3 Small RNA Sequencing
    8.4 De Novo Transcriptome Assembly
    8.5 Variant Calling and Transcriptome Epigenetics

9 Global NGS-based RNA Sequencing Market, By End User (Page No. - 76)
    9.1 Introduction
    9.2 Research Centers and Academic & Government Institutes
    9.3 Hospitals & Clinics
    9.4 Pharmaceutical & Biotechnology Companies
    9.5 Other End Users

10 Global NGS-based RNA Sequencing Market, By Region (Page No. - 82)
     10.1 Introduction
     10.2 North America
             10.2.1 U.S.
             10.2.2 Canada
     10.3 Europe
     10.4 Asia-Pacific
     10.5 Rest of the World

11 Competitive Landscape (Page No. - 102)
     11.1 Business Overview
     11.2 Vendor Inclusion Criteria
     11.3 Vendor Dive
             11.3.1 Vanguards
             11.3.2 Innovators
             11.3.3 Dynamic Players
             11.3.4 Emerging Players
     11.4 Competitive Benchmarking
             11.4.1 Product Offering (For All 25 Companies)
             11.4.2 Business Strategy (For All 25 Companies)

*Top 25 Companies Analyzed for This Study are - Illumina, Inc. (U.S.), Thermo Fisher Scientific (U.S.), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies (U.K.), Perkinelmer, Inc. , (U.S.), Qaigen N.V. (Germany), F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Gatc Biotech AG (Germany), Macrogen, Inc. (South Korea), Eurofins Scientific (Luxembourg), BGI (China), Takara Holdings Inc. (Japan), Cofactor Genomics, Inc. (U.S.), Otogenetics Corporation (U.S.), Nugen Technologies Inc. (U.S.), Hamilton Company (U.S.), Intrexon Corp. (U.S.), 10x Genomics, Inc. (U.S.), Personalis Inc. (U.S.), Genewiz, Inc. (U.S.), Medgenome Inc. (U.S.), Novogene Corporation (China), and Biomatters Ltd. (New Zealand)

12 Company Profiles (Page No. - 106)
(Overview, Products and Services, Financials, Strategy & Development)*
     12.1 Illumina, Inc.
     12.2 Thermo Fisher Scientific Inc.
     12.3 Pacific Biosciences of California, Inc.
     12.4 Qaigen N.V.
     12.5 F. Hoffmann-La Roche AG
     12.6 Agilent Technologies, Inc.
     12.7 BGI (Beijing Genomics Institute)
     12.8 Oxford Nanopore Technologies, Ltd
     12.9 Perkinelmer, Inc.
     12.10 Eurofins Scientific
     12.11 Gatc Biotech AG
     12.12 Macrogen, Inc.

*Details on Overview, Products and Services, Financials, Strategy & Development Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. - 145)
     13.1 Discussion Guide
     13.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.3 Introducing RT: Real-Time Market Intelligence
     13.4 Available Customizations
     13.5 Related Reports
     13.6 Author Details


List of Tables (42 Tables)

Table 1 Global NGS-based RNA-seq Market Snapshot (2017 vs 2022)
Table 2 Key RNA-seq Products Launched By Market Players (2015–2017)
Table 3 Global Market Size, By Product & Service, 2015–2022 (USD Million)
Table 4 Global Market Size, By Product & Service, By Region, 2015–2022 (USD Million)
Table 5 Global RNA-seq Sample Preparation Market Size, By Region, 2015–2022 (USD Million)
Table 6 Liquid Handling Systems: Key Products in the Market
Table 7 RNA-seq Platforms and Consumables Market Size, By Region, 2015–2022 (USD Million)
Table 8 RNA-seq Services Market Size, By Region, 2015–2022 (USD Million)
Table 9 RNA-seq Data Analysis, Storage, & Management Market Size, By Region, 2015–2022 (USD Million)
Table 10 Market Size, By Technology, 2015–2022 (USD Million)
Table 11 Market, By Region, 2015–2022 (USD Million)
Table 12 Market for Sequencing By Synthesis, By Region, 2015–2022 (USD Million)
Table 13 Market for Ion Semiconductor Sequencing, By Region, 2015–2022 (USD Million)
Table 14 Market for Single-Molecule Real-Time Sequencing, By Region, 2015–2022 (USD Million)
Table 15 Market for Nanopore Sequencing, By Region, 2015–2022 (USD Million)
Table 16 Market Size, By Application, 2015–2022 (USD Million)
Table 17 Market Size for Expression Profiling Analysis, By Region, 2015–2022 (USD Million)
Table 18 Market Size for Small RNA Sequencing, By Region, 2015–2022 (USD Million)
Table 19 Market Size for De Novo Transcriptome Assembly, By Region, 2015–2022 (USD Million)
Table 20 Market Size for Variant Calling and Transcriptome Epigenetics, By Region, 2015–2022 (USD Million)
Table 21 NGS-based RNA-seq Market Size, By End User, 2015–2022 (USD Million)
Table 22 Market Size for Research Centers and Academic & Government Institutes, By Region, 2015–2022 (USD Million)
Table 23 NGS-based RNA-seq Market Size for Hospitals & Clinics, By Region, 2015–2022 (USD Million)
Table 24 Market Size for Pharmaceutical & Biotechnology Companies, By Region, 2015–2022 (USD Million)
Table 25 Market Size for Other End Users, By Region, 2015–2022 (USD Million)
Table 26 Market Size, By Region, 2015-2022 (USD Million)
Table 27 North America: NGS-based RNA-seq Market Size, By Product & Service, 2015–2022 (USD Million)
Table 28 North America: Market Size, By Technology, 2015–2022 (USD Million)
Table 29 North America: NGS-based RNA-seq Market Size, By Application, 2015–2022 (USD Million)
Table 30 North America: Market Size, By End User, 2015–2022 (USD Million)
Table 31 Europe: NGS-based RNA-seq Market Size, By Product & Service, 2015–2022 (USD Million)
Table 32 Europe: Market Size, By Technology, 2015–2022 (USD Million)
Table 33 Europe: Market Size, By Application, 2015–2022 (USD Million)
Table 34 Europe: Market Size, By End User, 2015–2022 (USD Million)
Table 35 Asia-Pacific: NGS-based RNA-seq Market Size, By Product & Service, 2015–2022 (USD Million)
Table 36 Asia-Pacific: Market Size, By Technology, 2015–2022 (USD Million)
Table 37 Asia-Pacific: Market Size, By Application, 2015–2022 (USD Million)
Table 38 Asia-Pacific: Market Size, By End User, 2015–2022 (USD Million)
Table 39 RoW: NGS-based RNA-seq Market Size, By Product & Service, 2015–2022 (USD Million)
Table 40 RoW: Market Size, By Technology, 2015–2022 (USD Million)
Table 41 RoW: Market Size, By Application, 2015–2022 (USD Million)
Table 42 RoW:  Market Size, By End User, 2015–2022 (USD Million)


List of Figures (45 Figures)

Figure 1 Global NGS-based RNA-seq Market: Research Methodology Steps
Figure 2 Breakdown of Supply-Side Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market: Bottom-Up Approach
Figure 4 NGS-based RNA-seq Market: Top-Down Approach
Figure 5 Market: Data Triangulation
Figure 6 Global NGS-based RNA-seq Market, By Products & Services, 2017-2022
Figure 7 Global Market, By Technology, 2017–2022 (USD Million)
Figure 8 Global Market, By Application, 2017 vs 2022
Figure 9 Global Market, By End User, 2017–2022 (USD Million)
Figure 10 Global Market, By Region, Market Share (2017) & CAGR (2017–2022)
Figure 11 Advantages of RNA-seq Over Microarray Technology are A Major Factor Driving the Growth of the NGS-based RNA-seq Market
Figure 12 Sequencing By Synthesis Technology to Hold Large Market Share During the Forecast Period
Figure 13 Expression Profiling Analysis to Command A Major Share of the NGS-based RNA-seq Market in 2017
Figure 14 Research Centers and Academic & Government Institutes to Dominate the Global NGS-based RNA-seq Market in 2017 and 2022
Figure 15 Asia-Pacific to Register the Highest CAGR During the Forecast Period (2017 to 2022)
Figure 16 NGS-based RNA-seq Market: Drivers, Restraints, Opportunities, and Challenges
Figure 17 Global Funding Activities for RNA-seq and Microarray Projects, 2009–2016
Figure 18 Number of RNA-seq Publications Globally, 2011–2016
Figure 19 NGS-based RNA-seq Market, By Product & Service
Figure 20 Major Market Players in the RNA-seq Market
Figure 21 Major Steps in RNA-seq Sample Preparation
Figure 22 Library Preparation & Target Enrichment Segment Dominates the RNA-seq Sample Preparation Market in 2016
Figure 23 Nanopore Sequencing to Register the Highest CAGR During 2017 to 2022
Figure 24 Applications of NGS-based RNA-seq
Figure 25 Expression Profiling Analysis to Hold the Largest Share in the NGS-based RNA-seq Market in 2016
Figure 26 Expression Profiling Analysis Workflow
Figure 27 Small RNA Sequencing Workflow
Figure 28 Strategies for De Novo Transcriptome Assembly From RNA-seq Data
Figure 29 Variant Calling and Transcriptome Epigenetics for RNA-seq
Figure 30 Pharmaceutical & Biotechnology Companies to Register the Highest CAGR in the Forecast Period
Figure 31 Asia-Pacific to Grow at the Highest Rate During the Forecast Period
Figure 32 North America: NGS-based RNA-seq Market Snapshot
Figure 33 Europe: Market Snapshot
Figure 34 Asia-Pacific: NGS-based RNA-seq Market Snapshot
Figure 35 RoW: Market Snapshot
Figure 36 Vendor Dive: Evaluation Overview
Figure 37 Illumina, Inc.: Company Snapshot (2016)
Figure 38 Thermo Fisher Scientific: Company Snapshot (2016)
Figure 39 Pacific Biosciences of California, Inc.: Company Snapshot (2016)
Figure 40 Qaigen N.V.: Company Snapshot (2016)
Figure 41 F. Hoffmann-La Roche AG: Company Snapshot (2016)
Figure 42 Agilent Technologies, Inc.: Company Snapshot (2016)
Figure 43 Perkinelmer, Inc.: Company Snapshot (2016)
Figure 44 Eurofins Scientific: Company Snapshot (2016)
Figure 45 Macrogen, Inc.: Company Snapshot (2015)

The global NGS-based RNA-seq market is projected to reach USD 2.65 Billion by 2022 from USD 1.05 Billion in 2017, at a CAGR of 20.2% during the forecast period. The advantages of RNA-seq over microarray technology, technological advancements in RNA-seq products, increasing number of RNA-Seq grants, increasing number of research activities, and rapid growth in precision medicine are the key factors driving the growth of the market. On the other hand, lack of skilled professionals and standardization concerns of RNA-seq in diagnostic testing are some of the key factors limiting the growth of the market. The increasing applications of RNA-seq in research are expected to provide a wide range of growth opportunities for players in the market. Storage and interpretation of sequencing data and analysis of RNA-seq data for novel transcripts are expected to challenge market growth.

This report broadly segments the NGS based RNA-Seq market into products & services, technology, application, and end user. On the basis of product and service, the NGS market is categorized into sample preparation, sequencing platforms & consumables, sequencing services, and data analysis, storage, & management. In 2016, the sequencing platforms and consumables segment accounted for the largest share of the market.

On the basis of technology, the market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing. In 2016, the SBS technology accounted for the largest share of the market, majorly due to the development of new and advanced NGS platforms, the increasing demand for Illumina’s systems (including the HiSeq series and MiSeq), and the growing demand for NextSeq and HiSeq X Ten.

Based on applications, the market is categorized into four segments, namely, de novo transcriptome assembly, small RNA sequencing, expression profiling analysis, and variant calling & transcriptome epigenetics. The expression profiling analysis segment accounted for the major share of the market and expected to register the highest growth during the forecast period.

On the basis of end user, the market is segmented into research centers and academic & government institutes, hospitals & clinics, pharmaceutical & biotechnology companies, and other end users. Among these end users, the hospitals and clinics segment is expected to register the highest CAGR due to the growing number of agreements between companies and hospitals for the development of advanced tests and products catering to the specific needs of hospitals and clinics. For instance, in February 2016, Thermo Fisher Scientific and Children's Hospital Los Angeles (CHLA, U.S.) collaborated to develop a targeted RNA & DNA sequencing-based research gene-panel specifically for pediatric cancer.

This report covers the NGS market across four major geographies, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Of the four geographic regions studied in the report, North America is commanded the largest share of the market in 2016. However, Asia-Pacific is expected to register the highest growth rate during the forecast period, due to increasingly focus of key market players on strengthening their presence in the Asia-Pacific region. Globaly, the market growth is expected to be hindered by lack of skilled RNA-seq professionals across the globe.

NGS-based RNA-seq Market

The major players in the global market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N. V. (Germany), Pacific Biosciences of California, Inc. (U.S.), BGI (China), Oxford Nanopore Technologies, Ltd. (U.K.), PerkinElmer, Inc. (U.S.), GATC Biotech AG (Germany), Agilent Technologies, Inc. (U.S.), Roche Holding AG (Switzerland), Macrogen, Inc. (South Korea), and Eurofins Scientific (Luxembourg).

Illumina Inc. dominates the market through its wide range of technologically advanced and innovative platforms and associated RNA-seq products. The company adopts the strategy of product launches and company invests a significant amount of its revenue on R&D expenditure to maintain its leadership position in the market. For instance, in 2016, the company invested 21.0% of its revenue on R&D, as compared to 18.1% in 2015. The inorganic growth strategy includes strategic agreements with leading players in the market for the development of advanced technologies and strengthening of its research and commercialization capabilities. With its strong product portfolio and wide geographic presence, the company is expected to maintain its dominance in the market during the forecast period.

Thermo Fisher Scientific is another leading market player that offers extensive range of NGS-based RNA-seq products such as analytical instruments, equipment, reagents and consumables, and software & services. It entered the market through the acquisition of Life Technologies in 2014. The company adopts various organic and inorganic strategies such as agreements with leading pharmaceutical companies, for the development of NGS-based oncology tests for companion diagnostics. With its strong geographic presence and robust product portfolio, the company is expected to witness rapid growth in the market.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth Biotechnology Markets on KnowledgeStore
Request Demo